By Eshe Nelson Reporting from London Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Europe's largest pharmaceutical firm, Novo Nordisk, reported fourth-quarter earnings that surpassed analysts' expectations. The company’s shares jumped more than 6% at the market open in Europe ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Good day, and thank you for standing by. Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...

Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs. The Danish pharmaceutical giant reported turnover from ...